News releases | Absci Corp

Year

21 Mar / 24

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering

01 Mar / 24

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $4.50 per share,

27 Feb / 24

Absci Announces Pricing of Public Offering of Common Stock

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share,

27 Feb / 24

Absci Announces Proposed Public Offering of Common Stock

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.

21 Feb / 24

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after VANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling studies for

20 Feb / 24

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. TD Cowen 44 th Annual Health Care Conference in Boston, MA

10 Jan / 24

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI

08 Jan / 24

Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Preclinical data support profile for development of a potential best-in-class drug IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after VANCOUVER, Wash. and NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug

03 Jan / 24

Absci to Participate in the 26th Annual Needham Growth Conference

VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming 26 th Annual Needham Growth Conference.

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 19 of 19